DARTs Has Potential to Develop Novel Treatments for Gram
Positive/Negative Skin Opportunist Pathogens
Vyome
Biosciences, a clinical-stage specialty biopharmaceutical company
developing novel medicines for treating skin diseases caused by
resistant microbes, presented two posters at the Re-Entering
Antibacterial Discovery and Development Summit 2016 in Boston. The first
poster details how its Dual Action Rational Therapeutics (DARTs)
technology-based novel drug candidates may have the potential to bypass
and/or suppress antibiotic resistance for severe antibiotic-resistant
infections caused by orthopedic implants caused by S. epidermidis, a
skin opportunist pathogen. The second poster details the potential of
Vyome’s library of novel antibiotics currently in development for skin
opportunist pathogens, and their low propensity to develop antibiotic
resistance.
Vyome’s patented DARTs technology has the potential to improve treatment
of antibiotic-resistant infections from skin opportunist pathogens that
occur during orthopedic surgeries. Systemic antibiotics may be
ineffective in treating implant-related bone infections from
opportunistic pathogens during accident-associated or elective
orthopedic surgeries. Local antibiotic therapies, which are loaded into
bone cements, are also limited in efficacy due to poor drug penetration
through the bone, emergence of multi-drug resistant pathogens and
formation of bacterial biofilms. The company presented, “Development of
a New Generation Antibiotic for the Treatment of Orthopedic
Implant-Associated Infections Caused by Skin Opportunist Pathogens”
during a poster session this week.
“The rapid appearance and growth of resistant bacterial strains has far
reaching implications on public health around the world, and there is an
immediate need for additional, more effective treatment options for
infections caused by skin opportunist pathogens,” said Venkateswarlu
Nelabhotla (N. Venkat), Co-Founder and Chief Executive Officer of Vyome
Biosciences. “Where currently available systemic and locally
administered antibiotics fail, our multi-action DARTs platform has the
potential to achieve a high level of efficacy while minimizing the risk
of emerging resistance,” remarked Dr. Shiladitya Sengupta, Co-Founder &
Board Member, Vyome Biosciences.
As antibiotic resistant strains of both Gram-positive and Gram-negative
bacteria become more prevalent across many areas of care, Vyome aims to
address this large unmet need by developing a library of Dual Action
Rational Therapeutics technology platform based novel compounds by
utilizing a rational structure-based drug design to generate new
antibiotics which have multi-mode action to bypass and/or suppress
antibiotic resistance. Vyome aims to develop and leverage only molecules
with potent bactericidal activity against resistant strains, low
propensity in emergence of resistance, a demonstrable ability to disrupt
biofilms, and the exhibition of anti-inflammatory properties as the path
forward in treating local/topical infections caused by antibiotic
resistant skin opportunist pathogens. The company presented a study,
“Development of a Library of Novel Antibiotics with Low Propensity to
Develop Resistance” at the summit this week.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage specialty
bio-pharmaceutical company, which has novel platform technologies and a
deep pipeline that addresses drug-resistant skin opportunistic pathogens
such as antibiotic resistant acne. Vyome’s lead program VB 1953, which
targets the unmet need of antibiotic resistant acne, is currently under
evaluation in U.S. FDA Phase 1 clinical studies. Vyome also has a deep
pipeline of preclinical new chemical entities, unique in their ability
to overcome the development of resistance based on patented Dual Action
Rational Therapeutics (DARTs) technology. In addition, Vyome has
developed clinically proven antifungal products based on an innovative
technology platform, Molecular Replacement Therapy (MRT™). Vyome has
assembled a world-class team of scientific experts from India and the
United States who have a track record of conducting scientific research,
developing breakthrough products and building sustainable businesses.
More information is available at http://www.vyome.in
View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005837/en/
For Vyome BiosciencesNic DiBella, +1-617-945-5183nic@jpa.com
|